Loading clinical trials...
Loading clinical trials...
A Phase 1 Study Investigating AGEN1571 as a Single Agent and in Combination With a PD-1 Inhibitor and/or Botensilimab (AGEN1181) in Patients With Advanced Solid Tumors
Conditions
Interventions
AGEN1571
Balstilimab
+1 more
Locations
6
United States
USC Norris Comprehensive Cancer Center
Los Angeles, California, United States
Sarah Cannon Research Institute at HealthONE
Denver, Colorado, United States
Florida Cancer Specialists
Sarasota, Florida, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Icahn School of Medicine at Mount Sinai
New York, New York, United States
Lifespan Cancer Institute
Providence, Rhode Island, United States
Start Date
July 19, 2022
Primary Completion Date
December 23, 2024
Completion Date
December 23, 2024
Last Updated
April 30, 2025
NCT07181681
NCT05919264
NCT06257264
NCT07360314
NCT07403721
NCT07539285
Lead Sponsor
Agenus Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions